Scientists have found a way to fine-tune a central fat-control pathway in the liver, reducing harmful blood triglycerides ...
Researchers developed TLC-2716, a liver- and gut-targeted drug that selectively reduced LXR activity, lowering triglycerides, ...
In a Phase 1 clinical study, researchers led by EPFL and their partners report that a new liver- and gut-targeted oral drug ...